N-2(diethylamino)-ethoxyamine chlorohydrate

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-2(diethylamino)-ethoxyamine chlorohydrate
• 英文别名: 2-diethylaminoethoxyamine hydrochloride；O-[2-(diethylamino)ethyl]hydroxylamine;hydrochloride
• 化学式: C₆H₁₆N₂O*ClH
• 分子量: 168.667
• InChiKey: WMAVKPNBVWRHGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.64
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氟哌啶醇 、 N-2(diethylamino)-ethoxyamine chlorohydrate 在 吡啶 作用下， 以 乙醇 为溶剂， 反应 32.0h， 以76.9%的产率得到4-(4-chlorophenyl)-1-[4-[2-(diethylamino)ethoxyimino]-4-(4-fluorophenyl)butyl]piperidin-4-ol
  参考文献：
  名称：

  Synthesis of some novel oxime ether derivatives and their activity in the ‘behavioral despair test’

  摘要：

  In this study, a new series of 2-aminoethyloxime ether derivatives of some aralkylketones was synthesized. Their structures have been elucidated by UV, IR, H-1-NMR, C-13-NMR, mass spectra and elementary analysis. These compounds were then screened for their inhibition of immobility as an indicator of possible antidepressant activities by using the 'behavioral despair test'. Results showed that all the new compounds decreased the immobility time, however, the inhibition observed with A03, A04 and H01 was significantly higher compared to fluvoxamine (p < 0.01). (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(98)80038-x
• 作为产物：
  描述：

  N,N-diethylaminoethyl chloride hydrochloride 、 丙酮肟 在 盐酸 、 potassium carbonate 作用下， 以 乙醇 、 苯 为溶剂， 生成 N-2(diethylamino)-ethoxyamine chlorohydrate
  参考文献：
  名称：

  Symmetrical O-substituted dioximes of benzo-fused

  摘要：

  具有高抗癫痫和镇痛活性的药物由对称的β-二烷氧基亚胺环烯衍生物构成，其中亚胺双键与环双键或属于一个或多个融合苯环的双键共轭。它们对应于一般式I：##STR1##

  公开号：

  US04804684A1

文献信息

• [EN] MACROCYCLIC LACTONE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE LACTONE MACROCYCLIQUE ET LEURS UTILISATIONS
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2014118740A1

  公开（公告）日：2014-08-07

  The present invention provides compounds represented by Formula 1: wherein, R' is as defined in the specification, in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. The invention also relates to processes for the preparation of the compounds of Formula and pharmaceutical compositions containing them. The compounds and the pharmaceutical compositions of the present invention are useful for the treatment of inflammatory disorders and/or viral infections. The compounds and the pharmaceutical compositions of the present invention are also useful for the treatment of cancer.

  本发明提供了由式1表示的化合物：其中，R'如规范中所定义，在其所有立体异构体和互变异构体形式以及它们在所有比例上的混合物中，以及它们的药学上可接受的盐、药学上可接受的溶剂合物、药学上可接受的多晶形和前药。本发明还涉及制备上述式化合物的方法以及含有它们的药物组合物。本发明的化合物和药物组合物可用于治疗炎症性疾病和/或病毒感染。本发明的化合物和药物组合物也可用于治疗癌症。
• Aichinger,G. et al., Arzneimittel-Forschung/Drug Research, 1969, vol. 19, p. 838 - 845
  作者：Aichinger,G. et al.

  DOI：——

  日期：——
• Amide-oximes et hydroximates benzodioxaniques: synthèse de nouveaux composés et étude en neuropsycho-pharmacologie
  作者：C Davrinche、E Nguyen-Tri-Xuong、Y El Hamad、P Reynaud、P Rinjard、G Tran

  DOI：10.1016/0223-5234(92)90111-d

  日期：1992.11

  The authors describe the O(N)-(dialkylaminoalkyl) amide-oximes, benzodioxanic hydroximates and also the acetylated derivatives of the former compounds (I) which are detoxified. The hydroximates are obtained without structural ambiguity from thiono-esters. Pharmacological testing via the main methods shows that some of these new compounds possess imipraminic, and others neuroleptic properties.
• ASTOIN, J. N.;LEPAGE, F.;FROMANTIN, J. -R. M. J.
  作者：ASTOIN, J. N.、LEPAGE, F.、FROMANTIN, J. -R. M. J.

  DOI：——

  日期：——
• ASTOIN, J. N.;LEPAGE, F.;FROMANTIN, J. -P. M. J.
  作者：ASTOIN, J. N.、LEPAGE, F.、FROMANTIN, J. -P. M. J.

  DOI：——

  日期：——